


BAMOMAB

Anti-Human ULBP3 Monoclonal Antibody CUMO3

Antigen:	Human ULBP3 (UL16-binding protein 3)	
Clone:	CUMO3, mouse IgG1	
Catalog Number:	CUMO3-100	
Specificity:	binds: ULBP3 binds not: ULBP1, ULBP2, ULBP4 blocks: NKG2D binding to ULBP3	
Epitope:	in ULBP3 ectodomain	
Applications:	Flow cytometry	
Size:	100 µg, 1.0 mg/ml, in 0.1 ml phosphate-buffered saline, pH 7.4 with 0.05% sodium azide (Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing).	
Usage:	In general, for flow cytometry we recommend a final dilution of 10µg mAb/ml and for ELISA 1-10 µg mAb/ml.	
Purification:	Protein A affinity chromatography	
Storage:	Store at 4°C. For long-term storage freezing at -80°C is recommended.	
Description:	UL16-binding proteins (ULBP) have been discovered in 2001 during a search for human proteins binding the Human Cytomegalovirus-encoded UL16 glycoprotein [1] and for human homologues of the mouse RAE1 ligands of NKG2D, respectively [2]. ULBP1-4 are cell surface proteins with an MHC class I-like $\alpha 1/\alpha 2$ superdomain that is bound by human NKG2D [1-3]. ULBP1-3 are attached to the cell surface by GPI-anchor [1]. Expression of ULBP is induced by infection with Human Cytomegalovirus (HCMV) [4]. In contrast to ULBP1 and ULBP2, ULBP3 is not targeted by UL16 [1,4,5]. In vivo expression of ULBP3 is mostly unexplored, except that glioma and some freshly isolated leukemias have been shown to express ULBP3 [6,7]. Like other human and mouse NKG2D-ligands, ULBP stimulate tumor immunity in mice though binding of mouse NKG2D to ULBP3 could not be demonstrated [8]	
Conditions:	For research use only. Not for use in diagnostic or therapeutic procedures. BAMOMAB is not responsible for any patent infringements caused by the use of this product.	
Country of Origin:	Germany	
Literature:	<ol style="list-style-type: none">1. Cosman et al. <i>Immunity</i> 14,123-133 (2001).2. Steinle A et al. <i>Immunogenetics</i> 53, 279-287 (2001).3. Radaev S et al. <i>Immunity</i> 15,1039-1049 (2001).4. Welte S et al. <i>Eur J Immunol</i> 33, 194-203 (2003).5. Spreu J et al. <i>J Immunol</i> 177, 3143-3149 (2006).6. Eisele G et al. <i>Brain</i> 129, 2416-2425 (2006).7. Salih HR et al. <i>Blood</i> 102, 1389-1396 (2003).8. Sutherland C et al. <i>Blood</i> 108:1313-1319 (2006).	